ProKidney (PROK) reported second-quarter 2026 financial results and business updates, including completion of enrollment for patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis.
The company ended June 30, 2026, with $181.6 million in cash, cash equivalents and marketable securities, which it said supports operations into mid-2027.
- Q2 2026 revenue was $150,000, compared with $221,000 in the same period of 2025.
- Net loss before noncontrolling interest was $46.4 million for the quarter, compared with $37.0 million a year earlier.
- Net loss per share attributable to Class A common stock was $0.15 on a basic and diluted basis.
- Research and development expenses were $36.1 million, up from $25.9 million in Q2 2025.
- General and administrative expenses were $12.4 million, down from $14.0 million in the prior-year quarter.
- PROACT 1 accelerated approval efficacy topline results are anticipated in Q2 2027, with full enrollment targeted for the second half of 2026.
- ProKidney appointed Kenneth Locke as chief technical officer in June 2026.
$PROK Hedge Fund Activity
We have seen 44 institutional investors add shares of $PROK stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 3,810,111 shares (+274.7%) to their portfolio in Q2 2026, for an estimated $7,772,626
- STATE STREET CORP added 489,100 shares (+87.8%) to their portfolio in Q2 2026, for an estimated $997,764
- MILLENNIUM MANAGEMENT LLC added 437,041 shares (+23.8%) to their portfolio in Q1 2026, for an estimated $782,303
- MARSHALL WACE, LLP added 399,259 shares (+65.2%) to their portfolio in Q1 2026, for an estimated $714,673
- CITADEL ADVISORS LLC removed 371,797 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $665,516
- RENAISSANCE TECHNOLOGIES LLC added 355,089 shares (+39.6%) to their portfolio in Q1 2026, for an estimated $635,609
- GOLDMAN SACHS GROUP INC removed 259,259 shares (-38.1%) from their portfolio in Q1 2026, for an estimated $464,073
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
